科济药业-B(02171)发布公告，于2025年12月23日该公司斥资486.09万港元回购32万股，回购价格为每股 14.98-15.25港元。 ...

智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月23日该公司斥资486.09万港元回购32万 股，回购价格为每股14.98-15.25港元。 ...

格隆汇12月23日丨科济药业-B(02171.HK)公告，12月23日耗资486.1万港元回购32万股。 ...

FF305 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發 ...

Core Insights - The chairman of Kogei Pharmaceuticals, Li Zonghai, stated that universal CAR-T products are expected to reduce treatment costs to around 10,000 yuan per injection, significantly improving accessibility for patients [1][2][7]. Industry Overview - Currently, there are 7 CAR-T products approved in the U.S. and 8 in China, with the U.S. having a stronger commercial environment and payment capacity [3]. - China is improving its payment capabilities and policy environment, which may allow it to catch up with the U.S. in CAR-T product development [3]. Product Development - Kogei Pharmaceuticals has submitted the world's first NDA for a CAR-T product targeting solid tumors, expected to be approved by mid-next year [4]. - The company is focusing on both autologous and universal CAR-T products, with a shift towards universal CAR-T as a core growth engine due to its broader market potential and lower production costs [6][14]. Cost Reduction Strategy - The universal CAR-T product is projected to lower costs significantly, potentially to one-fiftieth of current prices, enhancing production efficiency and reducing failure rates [7]. - The company aims to have the first universal CAR-T product on the market by 2030, with a focus on overcoming challenges related to immune rejection [8][10]. Commercialization Efforts - Kogei's first commercial product, Saikeze, achieved revenue of 50.96 million yuan in the first half of 2025, marking a 703.8% year-on-year increase [11]. - The company is building its own commercialization team to support the launch of its products, particularly in the gastric cancer market, which has significant unmet clinical needs [12]. Global Expansion Plans - Kogei Pharmaceuticals plans to expand into Asian markets, including Hong Kong, Singapore, and South Korea, while also targeting Western markets where similar products are not available [13]. Future Research and Development - The company will prioritize funding for the development of universal CAR-T products and expanding the indications for its existing products [14].

Core Viewpoint - The CAR-T cell therapy is a revolutionary cancer immunotherapy method, but its high cost (up to millions) limits accessibility for many patients. However, there is potential for significant cost reduction with universal CAR-T products, which could lower the price to around 10,000 yuan per injection, enhancing drug accessibility [2][3]. Group 1: Market and Competitive Landscape - The global CAR-T product landscape shows strong development in the US and China, with 7 and 8 products approved respectively. The US has a stronger commercial environment and payment capacity compared to China, which is improving [8]. - China is synchronized with international standards in blood cancer CAR-T development and has a lead in solid tumor CAR-T products, with no overseas products in critical clinical stages yet [8]. - China is at the forefront of universal CAR-T technology, while it ranks among the top globally in autologous CAR-T development [8]. Group 2: Product Development and Cost Reduction - The first NDA for a solid tumor CAR-T product, CT041, is expected to be approved in the first half of next year [10]. - The company is focusing on developing universal CAR-T products, which are anticipated to have a broader market space and lower production and management costs [12][13]. - The cost of universal CAR-T products could potentially drop to one-fiftieth of the current autologous CAR-T costs, estimated at around 10,000 yuan per injection [14]. Group 3: Future Outlook and Challenges - The first universal CAR-T product is projected to be launched before 2030, with a timeline of approximately four years for clinical trials and regulatory approvals [16][17]. - A significant challenge in developing universal CAR-T products is addressing rejection issues, which many companies face. The company has a unique platform that shows promising early clinical trial data [18]. Group 4: Commercialization Strategy - The company has achieved significant revenue growth with its first commercial product, with a 703.8% increase in revenue year-on-year [20]. - The company is building its own commercialization team, anticipating that its products will meet substantial clinical needs in the domestic market, especially for gastric cancer [22]. - The company plans to expand its market reach to Asia and eventually to Europe and the US, where there are no similar products available [24]. Group 5: Research and Development Focus - Future R&D investments will prioritize expanding indications for CT041 and accelerating the market entry of universal CAR-T products [25]. - The company aims to lower the cost of solid tumor CAR-T products to around 10,000 yuan while achieving efficacy comparable to autologous products, which is crucial for broader accessibility [25].

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，12月18日，非执行董事郭华清增持科济药业（02171）1.8万股，每股作价 14.52港元，总金额约为26.14万港元。增持后最新持股数目约为2.25亿股，持股比例为39.01%。 责任编辑：卢昱君 香港联交所最新数据显示，12月18日，非执行董事郭华清增持科济药业（02171）1.8万股，每股作价 14.52港元，总金额约为26.14万港元。增持后最新持股数目约为2.25亿股，持股比例为39.01%。 责任编辑：卢昱君 ...

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (02171) by purchasing 18,000 shares at a price of HKD 14.52 per share, totaling approximately HKD 261,400, which reflects confidence in the company's future prospects [1] Group 1 - The total number of shares held by Guo Huaqing after the purchase is approximately 225 million shares [1] - The ownership percentage of Guo Huaqing in Kintor Pharmaceutical is now 39.01% [1]

智通财经APP获悉，香港联交所最新数据显示，12月18日，非执行董事郭华清增持科济药业(02171)1.8 万股，每股作价14.52港元，总金额约为26.14万港元。增持后最新持股数目约为2.25亿股，持股比例为 39.01%。 ...

Group 1: Market Overview - The pharmaceutical and biotechnology index decreased by 0.14% from December 15 to December 19, outperforming the ChiNext and CSI 300 indices [1][23] - The total trading volume in the pharmaceutical sector was 389.82 billion yuan, accounting for 4.49% of the total trading volume in the Shanghai and Shenzhen markets, which is below the average of 7.12% since 2013 [1][38] - The pharmaceutical sector ranked 18th in terms of weekly performance among all industries during the same period [1][25] Group 2: Sector Analysis - The recent lack of significant industrial catalysts has led to a muted beta effect in the sector, but many stocks have entered a value range, indicating potential for a rebound [2][59] - The "reward economy" theme has positively influenced certain pharmaceutical companies, particularly those linked to Ant Group and related retail channels [2][59] - Strong performance was noted in CXO, small nucleic acids, and certain innovative drugs, driven by specific stock factors such as BD expectations and overseas mapping [2][59] Group 3: In Vivo CAR-T Developments - In vivo CAR-T technology is expected to address the accessibility issues of CAR-T therapies, potentially lowering treatment costs and making it available as a shelf product [4][12] - Major pharmaceutical companies are actively investing in in vivo CAR-T, with business development (BD) transactions exceeding 5 billion USD, indicating its strategic importance [4][16] - Clinical data presented at the 2025 ASH meeting showed promising results for in vivo CAR-T therapies, with high rates of minimal residual disease (MRD) negativity in patients [4][19] Group 4: Future Outlook - The company maintains a positive outlook on innovation, international expansion, and turnaround opportunities in the pharmaceutical sector, focusing on BD 2.0, small nucleic acids, and supply chains as key investment areas [3][22] - The upcoming 2026 potential catalysts include the publication of the commercial insurance innovation drug directory and the commercialization of targeted CAR-T therapies [21][22] - Domestic companies are rapidly advancing in the in vivo CAR-T space, with several candidates in early clinical stages, indicating a growing competitive landscape [22][22]